<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00904449</url>
  </required_header>
  <id_info>
    <org_study_id>EN3202-022</org_study_id>
    <nct_id>NCT00904449</nct_id>
  </id_info>
  <brief_title>Open Label Assessment of Long-Term Safety and Utility</brief_title>
  <official_title>An Open-Label Assessment of the Long-Term Safety and Utility of NumorphanÂ® for the Relief of Moderate to Severe Pain in Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor the long-term analgesic effectiveness, safety, and
      utility of oxymorphone ER for the relief of moderate to severe pain due to cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of AEs and clinical laboratory values</measure>
    <time_frame>22 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Favorable long-term safety profile for oxymorhpone ER in the treatment of moderate to severe pain in patients with cancer</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxymorphone ER</intervention_name>
    <description>10mg, 20mg, and 40mg PO</description>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged &gt; 18 years with moderate to severe pain arising from cancer
             (histologically and/or clinically proven) who require chronic treatment with WHO step
             3 analgesics.

          -  Women of child-bearing potential must be using an approved method of contraception
             (hormone contraception, IUD, or double barrier method) and have a negative serum
             pregnancy test prior to entry into the study.

          -  Participated in study EN3202-018; the patient must have been treated with study
             medication and completed the exit visit to be eligible.

        Exclusion Criteria:

          -  Experienced a serious, adverse experience during study EN3202-018 that was possible or
             probably related to study medication.

          -  Withdrew from study EN3202-018 due to an Adverse experience possibly or probably
             related to study medication.

          -  Known idiosyncratic reaction or hypersensitivity to oxymorphone.

          -  Inability to take oral medication for 1 week.

          -  Patients with ileosomy, mechanical intestinal obstruction, partial or complete gastric
             outlet obstruction, parlayticileus, or other conditions that might contraindicate the
             use of, or impair the absorption of an oral controlled-release dosage form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2009</study_first_submitted>
  <study_first_submitted_qc>May 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2009</study_first_posted>
  <last_update_submitted>February 9, 2010</last_update_submitted>
  <last_update_submitted_qc>February 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sr. Director Clinical R&amp;D</name_title>
    <organization>Endo Pharmaceuticals</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxymorphone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

